Pricing Log in Create free account
Friday 6 November 2026 Export HALO’s income statement to Excel — free account

Halozyme Therapeutics, Inc.

HALO Healthcare Biotechnology

Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024.

Revenue
+39.2%
EPS
+45.6%
Free cash flow
−58.6%
Total debt
+115.1%

Quarter to September 2026, against a year earlier

103.93 19.03 −15.48%
Market cap
$14.0B
P/E
29.5×
Fwd P/E
17.9×
Dividend yield
—
F-score
5/9
Altman Z
3.46
Beneish M
−2.59
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Halozyme Therapeutics, Inc. 10-Q filed Nov 5, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 4:13 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 6, 2026: 23 added · 7 removed · 44 modified; 14 with only figures updated

  1. Modified · Overview

    As the innovators of ENHANZE® drug delivery technology (“ENHANZE”) with our proprietary enzyme, rHuPH20, our commercially validated commercially-validated solution is used to facilitate the subcutaneous (“SC”) delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reducedreducing treatment burden. We license our technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with our partners’ proprietary compounds. We are also developing partner products with HyperconTM drug delivery technology (“Hypercon technology”) and developing the AeroconTM drug delivery technology (“Aerocon technology”), previously referred to as Surf Bio drug delivery technology, to expand the breadth of our drug delivery technology portfolio. Hypercon technology is an innovative microparticle technology that has been demonstrated in non-clinical testing to enable hyperconcentration of drugs and biologics and reduce the injection volume for the same dosage and potentially expanding